• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
MacroGenics, Inc. - Product Pipeline Review - H2 2011 Product Image

MacroGenics, Inc. - Product Pipeline Review - H2 2011

  • Published: November 2011
  • 63 pages
  • Global Markets Direct

MacroGenics, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “MacroGenics, Inc. - Product Pipeline Review - H2 2011” provides data on the MacroGenics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MacroGenics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from MacroGenics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MacroGenics, Inc. - Brief MacroGenics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MacroGenics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
MacroGenics, Inc. Snapshot
MacroGenics, Inc. Overview
Key Information
Key Facts
MacroGenics, Inc. – Research and Development Overview
Key Therapeutic Areas
MacroGenics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
MacroGenics, Inc. – Pipeline Products Glance
MacroGenics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
MacroGenics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
MacroGenics, Inc. – Drug Profiles
DART For Autoimmune Disorders
DART mAb
MGA271
MGAH22
MGAWN1
Monocloncal Antibodies
Monocloncal Antibodies For Pathogens
RAV12 + Gemcitabine
MacroGenics, Inc. – Pipeline Analysis
MacroGenics, Inc. – Pipeline Products by Therapeutic Class
MacroGenics, Inc. - Pipeline Products By Target
MacroGenics, Inc. – Pipeline Products by Route of Administration
MacroGenics, Inc. – Pipeline Products by Molecule Type
MacroGenics, Inc. – Recent Pipeline Updates
MacroGenics, Inc. - Dormant Projects
MacroGenics, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Teplizumab
MacroGenics, Inc. – Company Statement
MacroGenics, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 15, 2010: MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding further Advances DART Platform and Infectious Disease Portfolio
Jul 08, 2010: Green Cross Signs Collaboration Agreement With MacroGenics To Develop And Market MGAH22
Jan 06, 2011: MacroGenics Starts Phase I Clinical Trial Of MGAH22 For Patients With HER2-Expressing Solid Tumors
Oct 01, 2010: Green Cross Announces IND Approval Of New Anti-Cancer Drug MGAH22 For Multinational Phase I Study
Financial Deals Landscape
MacroGenics, Inc., Deals Summary
MacroGenics, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
MacroGenics Acquires Anti-CD3 Monoclonal Antibody From Tolerance
Venture Financing
MacroGenics Secures $12 Million In Venture Financing
MacroGenics Secures $25 Million In Series D-2 Financing
MacroGenics Secures $45 Million In Series C Financing
MacroGenics Secures $30.5 Million In Series B Financing
MacroGenics Secures $13.5 Million In Series A Financing
Partnerships
PolyTherics Enters Into Co-Development Agreement With MacroGenics
Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics
Neose Technologies Enters Into Research Agreement With MacroGenics
Licensing Agreements
MacroGenics Enters Into Licensing Agreement With OriGene Technologies
MacroGenics Enters Into Licensing Agreement With Pfizer
Eli Lilly Enters Into Licensing Agreement With MacroGenics
Asset Transactions
MacroGenics Acquires Anti-CD3 Monoclonal Antibody From Tolerance
Acquisition
MacroGenics Acquires Raven biotechnologies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
MacroGenics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
MacroGenics, Inc. – Pipeline by Stage of Development, H2 2011
MacroGenics, Inc. – Monotherapy Products in Pipeline, H2 2011
MacroGenics, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
MacroGenics, Inc. - Phase II, H2 2011
MacroGenics, Inc. - Phase I, H2 2011
MacroGenics, Inc. - Pipeline By Therapeutic Class, H2 2011
MacroGenics, Inc. - Pipeline By Target, H2 2011
MacroGenics, Inc. – Pipeline By Route of Administration, H2 2011
MacroGenics, Inc. – Pipeline By Molecule Type, H2 2011
MacroGenics, Inc. – Recent Pipeline Updates, H2 2011
MacroGenics, Inc. - Dormant Developmental Projects, 2010
MacroGenics, Inc. - Discontinued Pipeline Products, 2010
MacroGenics, Inc., Other Locations
MacroGenics, Inc., Subsidiaries
MacroGenics, Inc., Deals Summary
MacroGenics Acquires Anti-CD3 Monoclonal Antibody From Tolerance
MacroGenics Secures $12 Million In Venture Financing
MacroGenics Secures $25 Million In Series D-2 Financing
MacroGenics Secures $45 Million In Series C Financing
MacroGenics Secures $30.5 Million In Series B Financing
MacroGenics Secures $13.5 Million In Series A Financing
PolyTherics Enters Into Co-Development Agreement With MacroGenics
Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics
Neose Technologies Enters Into Research Agreement With MacroGenics
MacroGenics Enters Into Licensing Agreement With OriGene Technologies
MacroGenics Enters Into Licensing Agreement With Pfizer
Eli Lilly Enters Into Licensing Agreement With MacroGenics
MacroGenics Acquires Anti-CD3 Monoclonal Antibody From Tolerance
MacroGenics Acquires Raven biotechnologies

List of Figures
MacroGenics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
MacroGenics, Inc. – Pipeline by Stage of Development, H2 2011
MacroGenics, Inc. – Monotherapy Products in Pipeline, H2 2011
MacroGenics, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
MacroGenics, Inc. – Pipeline By Therapeutic Class, H2 2011
MacroGenics, Inc. - Pipeline By Target, H2 2011
MacroGenics, Inc. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS